| Prev Close | 4.44 |
| Day Low/High | 4.52 / 4.82 |
| 52 Wk Low/High | 3.62 / 17.37 |
Clovis Oncology, Inc. (CLVS)
4.76
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 88.32B |
| Market Cap | 392.14M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs
This is why I always have some 'dry powder' to deploy during these temporary hiccups.
Names to Watch Amid Biotech's Nascent Rally
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
4 Names to Buy in a Refreshed Biotech Space
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Two Oncology Stocks I Like Now
M&A activity should pick up in the biotech space.
Some Biotech Stocks to Add Exposure To
Secondary offerings create buying opportunities.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Markets Drift Lower
Markets have drifted down since our last update at 11am EST. All major averages are now in the red for the day. Dropbox  looks like it will have a strong debut on the market with its IPO 25 times oversubscribed. The biotech sector is slightly up tod...
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
Bret Jensen's Biotech Mailbag
We'll answer two of the common questions we have received so far in March.
Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
These Stocks Show a Change of Direction
Finding bullish and bearish reversals in the market.
Look for Clovis Oncology to Resume Its Advance
More gains await patient CLVS holders.
Biotech Heating up on M&A Speculation
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro  is not giving up its big takeover speculation rise yesterday and is up another 3%...
Tesaro, Clovis Oncology Lifting Biotechs
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences  is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
Big-Cap Tech Names, Biotechs, Oils Lifting Market
The number of new 12-month highs has climbed to 240.
Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug
A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.
Here's Why Shares of Clovis Oncology Are Higher Wednesday
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.
Clovis Oncology Charts Suggest Aggressive Buying
The technical signs indicate the stock's price and volume are going up without a dip.
Morning Movers: MYL, XOM, MSFT, GIS, CLVS
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
Clovis Oncology Is a Great Example of How Technical Analysis Can Fail
Fundamentals trumped technical analysis in a big way.
Three Speculative Biotech Plays
Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.
